<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - Ambrx Presents New Phase 1 Trial Results for Lead Program ARX788
Image Overlay - Ambrx Presents New Phase 1 Trial Results for Lead Program ARX788

Ambrx Presents New Phase 1 Trial Results for Lead Program ARX788

Ambrx Presents New Phase 1 Trial Results for Lead Program ARX788

Ambrx has presented new results on their lead program ARX788, a homogeneous and highly stable, site-specific antibody drug conjugate targeting HER2 positive cancers. "[...] Phase 1 studies demonstrated promising antitumor activity in heavily pre-treated cancer patients at the recommended Phase 2 dose", said Joy Yan, MD, PhD, Ambrx Chief Medical Officer. The randomized controlled Phase 2/3 has treated 22 subjects and continues to enroll patients quickly. Yourway is delighted about the positive results and continues to support the fight against cancer.

Back to Index
Media

Upcoming Events

Evolution Summit

September 20-22, 2021
Boston, MA

Media

Articles

Wendy Xia Stands at the Intersection of Science and Heart

Open chat
Come chat with us!
Hello! How can I help you?